Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial
Date: June 15, 2010 Source: Cephalalgia
Download the PDF »
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan
Date: June 15, 2010 Source: Cephalalgia
Download the PDF »
Prediction of Therapeutically Effective Dose of COL-144 Based on Relationship Between Plasma Concentrations and Headache Response
Date: September 11, 2009 Source: 14th International Headache Congress; Philadelphia, PA
Download the PDF »
COL-144 an Orally Bioavailable Selective 5-HT1F Receptor Agonist for Acute Migraine Therapy
Date: September 11, 2009 Source: 14th International Headache Congress; Philadelphia, PA
Download the PDF »
COL-144: A Selective 5-HT1F Agonist For the Treatment of Migraine Attacks
Date: September 5, 2008 Source: European Headache & Migraine Trust International Congress 2008; London, England, Poster #PC.11
Download the PDF »
COL-144: Preclinical Profile of a Selective 5-HT1F Receptor Agonist for Migraine
Date: September 5, 2008 Source: European Headache & Migraine Trust International Congress 2008; London, England, Poster #PC.12
Download the PDF »